0000950170-24-069890.txt : 20240606
0000950170-24-069890.hdr.sgml : 20240606
20240606161316
ACCESSION NUMBER: 0000950170-24-069890
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240604
FILED AS OF DATE: 20240606
DATE AS OF CHANGE: 20240606
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: JOYCE MARTIN JOSEPH
CENTRAL INDEX KEY: 0001300858
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36332
FILM NUMBER: 241025182
MAIL ADDRESS:
STREET 1: 1050 HINGHAM STREET
CITY: ROCKLAND
STATE: MA
ZIP: 02370
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aldeyra Therapeutics, Inc.
CENTRAL INDEX KEY: 0001341235
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
BUSINESS PHONE: 781-761-4904
MAIL ADDRESS:
STREET 1: 131 HARTWELL AVENUE
STREET 2: SUITE 320
CITY: LEXINGTON
STATE: MA
ZIP: 02421
FORMER COMPANY:
FORMER CONFORMED NAME: Aldexa Therapeutics, Inc.
DATE OF NAME CHANGE: 20130102
FORMER COMPANY:
FORMER CONFORMED NAME: Neuron Systems Inc
DATE OF NAME CHANGE: 20051012
4
1
ownership.xml
4
X0508
4
2024-06-04
0001341235
Aldeyra Therapeutics, Inc.
ALDX
0001300858
JOYCE MARTIN JOSEPH
C/O ALDEYRA THERAPEUTICS, INC.
131 HARTWELL AVENUE
LEXINGTON
MA
02421
true
false
false
false
false
Stock Option (Right to Buy)
4.09
2024-06-04
4
A
false
40282
0
A
2034-06-03
Common Stock
40282
40282
D
Stock Option (Right to Buy)
4.09
2024-06-04
4
A
false
1215
0
A
2034-06-03
Common Stock
1215
1215
D
Stock Option (Right to Buy)
4.09
2024-06-04
4
A
false
5209
0
A
2034-06-03
Common Stock
5209
5209
D
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Nominating/Corporate Governance Committee of the Board of Directors of the Issuer through the applicable vesting date.
Exercisable with respect to 100% of the shares on the one-year anniversary of the grant date, provided that the Reporting Person provides continuous service as a member of the Audit Committee of the Board of Directors of the Issuer through the applicable vesting date.
/s/ Martin Joyce
2024-06-06